Monday, 17 February 2020

Gene Expression Analysis Market Growth Opportunities, Analysis and Forecasts Report 2019-2023

Gene Expression Analysis Research Report: Information by Product (Consumables & Instruments), Service (Gene Expression Profiling & Others), Application (Drug Discovery & Others), End User (Academic & Research Institutes & Others) - Forecast till 2023
Market Scenario:
Gene expression analysis is research dedicated towards functional genomics extending the application purview of studying genes and gene transcripts. Synthesizing functional gene products such as functional RNAs and protein species offers insights on how an intact organism survives when a particular gene goes missing. Growth in personalized medicine and technological developments are driving market growth. According to a data published by the Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicines in 2017. Moreover, the development of genomic databases and increased government funding towards genomics is fueling market growth.
However, the lack of skilled labor and the high cost of instruments may hamper market growth during the assessment period.
The Global Gene Expression Analysis Market Size is expected to grow significantly over the forecast period. It is estimated that the global gene expression analysis market is expected to hold a market value of USD 3.250 million and register a CAGR ~9.1% during the forecast period of 2018 to 2023.
Segmentation
The global gene expression analysis market has been segmented into product, services, application, end-user, and region.
The market, on the basis of product, has been segmented into consumables and instruments.
The market, based on consumables, has been further segmented into reagents and DNA chips.
The market, based on instruments, has been further segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others.
The market, by services, has been segmented into gene expression profiling services, sequencing services, bioinformatics solutions, and others.
The market, by application, has been segmented into drug discovery, diagnosis, research, and others.
The market, by end-user, has been segmented into pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gene expression analysis market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gene expression analysis market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The gene expression analysis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gene expression analysis market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Some of the key players in the global gene expression analysis market are GENERAL ELECTRIC COMPANY, Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Pacific Biosciences of California, Inc., BGI, PerkinElmer Inc., Agilent Technologies, Inc., QIAGEN, Oxford Gene Technology, Eurofins Scientific, Danaher, Genotypic Technology Pvt Ltd, Macrogen Inc.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global gene expression analysis market owing to the increasing research activities and the rising popularity of gene expression tests. Additionally, the well-developed healthcare sector is anticipated to boost the American gene expression analysis market.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing investment from governments in the field of genomics, and continuously developing economies. According to a report published by the International Journal of Social and Developmental Concerns in October 2017, in Malaysia, the growth of the public primary, as well as secondary care facilities, has decreased in the past few years, and it has not kept pace with the rapid urbanization. Thus, such factors restraint the growth of the market in this region. On the other hand, the Middle East & Africa has the least share of the market.
Europe is expected to hold the second largest position in the global gene expression analysis market. The market growth in this region is attributed to the availability of funds for research.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Robot-Assisted Surgical Systems Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 – 2023

Global Robot-Assisted Surgical Systems Market Research Report, by Product (Surgical Robot, Rehabilitation Robot, Non-Invasive Radiosurgery Robot), Application (Neurology, Orthopedic, Laparoscopy), End User (Healthcare Provider, Payer) –Forecast Till 2023
Market Insights:
The increasing need for automation in the healthcare industry and the shifting trend towards advanced robotic surgeries is anticipated to fuel the growth of the market. The high initial costs and adverse reports stand is expected to hamper the growth of the market.
Robot-assisted surgical systems industry will witness a widespread adoption since the introduction of the da Vinci surgical system by Intuitive Surgical Inc. After the system got FDA approval in 2000, da Vinci surgical system became the most widely-used surgical robot in the United States and Europe helping many cases to witness reduced length of hospital stays and lower rates of infection.
The Global Robot-Assisted Surgical Systems Market is projected to grow significantly over the forecast period. It is estimated that the global robot-assisted surgical systems market is expected to register a CAGR of ~10% during the forecast period of 2018–2023.
The global robot-assisted surgical systems market is conquered by several players. The key players are involved in new product launches, as well as strategic collaborations to brace their position in the market. For instance, in May 2015, Medtech expanded its presence in Asia with the sales of three ROSA Surgical Robots during April. This initiative is anticipated to open new avenues for the firm to cater to the untapped markets in this region.
Key Players
  • Stryker Corporation (MAKO Surgical Corp.),
  • Renishaw Plc,
  • Varian,
  • Accuray,
  • Intuitive Surgical Inc,
  • Health robotics S.R.L,
  • Smith & Nephew Plc. (Blue Belt Technologies, Inc.),
  • Auris Surgical Robotics, Inc. (Hansen Medical Inc.),
  • KUKA AG,
  • Mazor Robotics,
  • Medtronic plc,
  • THINK Surgical Inc.,
  • Zimmer Biomet Holdings Inc.,
  • Transenterix,
  • Verb Surgical,
  • Titan Medical,
  • Microbot Medical,
  • Medrobotics
Segmentation
The Global Robot-Assisted Surgical Systems Market is segmented on the basis of product, application, and end user.
Surgical robots are divided into orthopedic surgical robots, robotic neurosurgical systems, and laparoscopy robotic systems. Orthopedic Surgical Robots is divided into an iBlock surgical system, Robodoc surgical system, Navio PFS surgical system, MAKO RIO surgical system, and Stanmore Sculptor surgical system. Neurosurgical Robotic Systems is divided into Pathfinder surgical system, NeuroMate surgical system, and Renaissance surgical system. Laparoscopy Robotic Systems is divided into FreeHand endoscope holder system, Da Vinci robotic surgery system, Telelap ALF-X surgical system, and Steerable Robotic Catheters.
The robot-assisted surgical systems market by product is categorized into surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and emergency response robotic systems.
Rehabilitation robots are categorized into assistive robots, prosthetics, orthotics, therapeutic robots, and robotic exoskeleton systems. Hospital and pharmacy robots are categorized into telemedicine robots, IV robots, pharmacy robots, and cart transportation robots.
Based on application, the robot-assisted surgical systems market is segmented into neurology, orthopedics robotic systems, laparoscopy, and special education.
On the basis of end user, the market is segmented into healthcare providers, healthcare payers, and others.
On the basis of region, the global robot-assisted surgical systems market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The robot-assisted surgical systems market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
It is projected that the Americas dominated the global robot-assisted surgical systems market owing to the growth of the market in the North American region. This is largely attributed to factors such as well-established healthcare infrastructure and the increase in adoption of robotic surgical systems across various healthcare settings will support market growth in this region. Europe is expected to hold the second largest share in the robot-assisted surgical systems market owing to the introduction of advanced robot-assisted laparoscopic procedures and quality of treatment of existing and new medical indications.
Asia-Pacific was projected to be the fastest growing region for the global robot-assisted surgical systems market. With the growth of the overall robotics market in the region headed by technology giants like Japan and China, the availability of medical robots has also increased. In 2017, a robot performed the world’s first automated dental implant in China. The Middle East and Africa holds the least share in the global robot-assisted surgical systems market due to the presence of economically diverse countries, and fewer initiatives taken by the government.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Live Cell Encapsulation Market: Advancements, Key Players, Strategies to Boost Industry Growth 2023

Global Live Cell Encapsulation Market Research Report: By Manufacturing Technique (Simple Dripping, Electrostatic Dripping, & Others), Polymer Type (Alginate, HEMA-MMA, Chitosan, PAN-PVC, & Others), Application (Drug Delivery & Others)-Forecast till 2023
Market Scenario:
The global live cell encapsulation market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in August 2018, Balchem Italia S.r.l., a wholly owned subsidiary of Balchem Corporation, acquired Bioscreen Technologies, S.r.l., a privately held manufacturer of encapsulated and fermented feed nutrition ingredients. With this, the company aims to expand its position in the market.
The Global Live Cell Encapsulation Market is expected to grow significantly over the forecast period. It is estimated that the global live cell encapsulation market is expected to register a CAGR ~ 3.22% during the forecast period of 2018 to 2023, with an estimated market value of USD 249.87 million in 2017.
Numerous factors such as a high level of research activities in live cell encapsulation technologies and the rising awareness programs in various countries are anticipated to fuel the growth of the market. Moreover, the increasing investments by various public and private organizations have created a lucrative option for many companies to invest in providing new encapsulation techniques, leading to the overall growth of the market. Furthermore, the inclination towards novel drug delivery systems for disease management fuels the growth of the market during the forecast period.
However, the lack of skilled technicians, and ethical and legal issues, and unaffordability of various small-scale companies to enter the market due to high product manufacturing costs are expected to curb the growth of live cell encapsulation market. Moreover, the availability of high-quality raw material is also restraining the growth of the market.
The Global Live Cell Encapsulation Market is driven by factors such as rising demand for clinical efficacy of cell encapsulation technologies and growing awareness related to the clinical role of encapsulated cells to treat different chronic diseases. Additionally, encapsulation provides the durability and stability of the nutrient during handling and storage. Thus, such benefits of this technique are luring the competitors to enter the market.
Key Players
Balchem Corporation, Evonik Industries, Merck KGaA, BÜCHI Labortechnik AG, Lycored, Blacktrace Holdings Ltd., Living Cell Technologies, Reed Pacific Pty Limited, MiKroCaps, Biotime, Inc., Neurotech Holdings, LLC, Sernova Corporation, Encapsys, LLC, Sigilon Therapeutics, Inc., and Viacyte, Inc. are some of the key players in the global live cell encapsulation market.
Segmentation
The Global Live Cell Encapsulation Market has been segmented into manufacturing technique, polymer type, and application. The market, based on manufacturing technique, has been segmented into simple dripping, electrostatic dripping, coaxial airflow, rotating disk atomization, and others. The market, by polymer type, has been further segmented into alginate, HEMA-MMA, Chitosan, silica, cellulose sulfate, PAN-PVC, and others. The market, by application, has been segmented into drug delivery, regenerative medicine, cell transplantation, and others. The drug delivery segment is expected to hold a major share owing to the increasing use of live cell encapsulation techniques in drug delivery systems. The segment of regenerative medicine is expected to be the fastest growing segment due to the rising trend and benefits of encapsulation in the tissue engineering field.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The live cell encapsulation market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European live cell encapsulation market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The live cell encapsulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The live cell encapsulation market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is expected to dominate the global live cell encapsulation market due to the increasing per capita healthcare expenditure, and the heavy adoption of new technology.
Furthermore, rising expenses in research and development by healthcare bodies and the government is anticipated to drive thegrowth of the market in this region. Apart from this, increasing applications of regenerative medicine in the US is expecting to push the growth of live cell encapsulation market. For instance, According to the National Institutes of Health (NIH), approximately 5,00,000 Americans benefit from a transplant each year.
Europe showed a considerable amount of growth in the global live cell encapsulation market. The market growth in this region is because of the presence of a well-established healthcare system and increase in chronic diseases. For instance, according to cancer research UK, there were approximately 9, 921 cases of cancer diagnosed in 2015. Such high rates of cancer are likely to increase demand for the use of next-generation sequencing as well as increase the market demands for monoclonal bodies and cellular research. These factors are expected to have a positive impact on the live cell encapsulation market.
Asia-Pacific is expected to have a sturdy growth rate during the forecast period owing to the huge patient pool of chronic diseases and government initiatives of healthcare reforms. However, less capital investment is restricting the market growth of this region.
On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income. Moreover, the limited adoption of advanced healthcare facilities and limited access to treatment facilities is also expected to drive the growth of the market in the near future.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Soft Tissue Repair Market Size, Emerging Technologies, Future Trends, Competitive Analysis and Segments Poised for Strong Growth in Future 2023

Global Soft Tissue Repair Market Research Report: By Product (Fixation, Tissue Patch/Match, & Others), Application (Orthopedic, Skin Repair, Hernia, Vaginal Sling, Dental Reconstruction), End User (Hospitals, Clinics & others)—Global Forecast till 2023
Market Insights:
The Global Soft Tissue Repair Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5200 million in 2017 and is projected to register a CAGR of 6.2% over the forecast period.
Various other factors such as increasing awareness about orthopedic disorders and other related conditions, improvement in reimbursement policies, untapped emerging markets, and increasing healthcare expenditure are also expected to propel the growth of the market.
The xenograft implant is designed for the surgical repair of damaged or ruptured membranes. The rising cases of sports-related injuries and technological advancements are some of the key factors driving the soft tissue repair market. For instance, in 2016, Colorado Therapeutics received FDA approval for its xenograft implant.
However, the high cost of advanced equipment and a shortage of physicians in emerging markets can hamper market growth over the forecast period.
Key Players
Some of the key players in the global soft tissue repair market are Stryker Corporation, C.R. Bard, Inc., Arthrex, Inc., Integra LifeScience Corporation, Depuy Synthes, Smith & Nephew plc, Allergan Plc., Athersys, Inc., CryoLife, Inc., Medtronic Plc., Organogenesis Inc., Zimmer Biomet Holdings, Inc., Lifenet Health, Inc., American Medical Systems Inc., U.S. Stem Cell, Inc., Wright Medical Group, Inc., Isto Biologics, and others.
Segmentation
The global soft tissue repair market is segmented based on product, application, end user, and region.
the global market for soft tissue repair, by product, is segmented into fixation products, tissue patch/match, laparoscopic instrument, and others. The fixation products segment is further classified as a suture, suture anchors, and interference screw. The tissue patch/match segment is further classified as biological, and synthetic. The biological segment includes allograft and xenograft.
Based on application, the market is segmented into orthopedic surgery, skin repair, hernia repair, vaginal sling repair, dental reconstruction, cardiovascular surgery, breast reconstruction, and others.
Based on end user, the market is segmented into hospitals, clinics, research & academic institutes, and others.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The soft tissue repair market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European soft tissue repair market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The soft tissue repair market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The soft tissue repair market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for soft tissue repair owing to the increasing healthcare expenditure presence of major market players and rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058.
In 2017, it was estimated that Europe stood second in the global soft tissue repair market. Robust research and development (R&D) sector along with the availability of funding opportunities in research and innovation will support the market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to increasing demand for medical technology, growing health awareness, and growing aging population coupled with the rising prevalence of orthopedic diseases in India, Japan, and Australia. For instance, according to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, around 12.4% of the population in the region was 60 years or older and is projected to reach to more than 1.3 billion by 2050.
On the other hand, the Middle East and Africa held the least share in the global soft tissue repair market due to the low economic development, especially within the African region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Overactive Bladder Treatment Market 2019 Global Analysis, Growth, Size, Share, Trends, Forecast to 2023

Market Scenario:
Overactive bladder is a condition that occurs in various diseases such as Parkinson's disease, multiple sclerosis, stroke, and others. Rise in prevalence of these diseases and rapid increase in the global geriatric population are inducing high demand for effective treatment of overactive bladder, which in turn is propelling the growth of the global overactive bladder treatment market. Increased marketing activities, availability of affordable treatments and development of innovative treatment procedures are also fueling the growth of the global overactive bladder treatment market. However, low penetration of treatment options in the healthcare sector and lack of awareness among the population of the underdeveloped countries are restricting the expansion of the global overactive bladder treatment market during the assessment period.
The global overactive bladder treatment market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global overactive bladder treatment market is expected to register a CAGR of ~ 3.1% during the forecast period of 2018–2023.
Despite the drivers, lack of awareness in developing countries and undesired systemic effects of some current treatment options may hinder the growth of the market during the assessment period.
Company Profiles    
  • Astellas Pharma Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical
  • Allergan, Plc. 
  • Mylan N.V. 
  • Endo International Plc 
  • Hisamitsu Pharmaceutical Co., Inc.
  • Sanofi S. A.
  • Aurobindo Pharma Limited 
  • Johnson & Johnson
  • Intas Pharmaceuticals Ltd. 
  • Apotex Inc. 
  • Macleods Pharmaceuticals Ltd. 
  • Medtronic PLC
  • Cogentix Medical, Inc.
  • Others
Segmentation
The global overactive bladder treatment market is segmented on the basis of pharmacotherapy, non-pharmacological treatment, and disease.
On the basis of pharmacotherapy, the market is classified into anticholinergics, Botox, mirabegron, neurostimulation, and others. Further, anticholinergics are classified into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium, and others.
The global overactive bladder treatment market on the basis of non-pharmacological treatment is segmented into dietary and fluid modifications, behavioral therapy, pelvic floor muscle rehabilitation, and others.
On the basis of disease, the market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Further, the neurogenic overactive bladder is segmented into the overactive bladder in Parkinson’s disease, the overactive bladder in stroke, the overactive bladder in spinal cord injury, and overactive bladder in other disorders.
Geographically, the global overactive bladder treatment market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The overactive bladder treatment market in the Americas is further segmented into North America and South America. North America is further classified as the US and Canada.
The overactive bladder treatment market in Europe is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe.
The overactive bladder treatment market in Asia-Pacific is segmented into Japan, China, India, Republic of Korea, Australia, and the rest of Asia-Pacific.
The overactive bladder treatment market in the Middle East and Africa is segmented into the Middle East and Africa.
Regional Market Summary
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Posted by at No comments:
Labels:

Optical Imaging Market 2019 World Analysis and Forecast to 2023

Market Scenario
Optical imaging has the ability to improve point of care in the healthcare setting since it provides improved screening and detection of disease. The global optimal imaging market is anticipated to attain a valuation of USD 1.92 Bn at a CAGR of 10% over the forecast period of 2018-2023, projects Market Research Future (MRFR) in an extensive study.
Some of the Top Key Players in Optical Imaging Market are Jude Medical, Inc., Carl Zeiss Meditec AG, Bioptigen, Inc., Canon Inc, Heidelberg Engineering, Inc., Topcon Corporation, Perkinelmer, Inc., Koninklijke Philips N.V. and Agfa-Gevaert N.V. etc.
Driven by critical healthcare needs, optimal imaging is gaining traction as a detector technology. Optimal imaging is a technique where cellular and molecular function in a living body is interrogated with the help of light and the special properties of photons to obtain detailed images of organs and tissues.
Optical imaging is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of optical imaging techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market.
However, factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for optical imaging procedures restrict market growth.
Segmentation
The global optical imaging market is segmented on the basis of products, techniques, therapeutic area, application, and end-user. Considering the type of product, the market is segmented into imaging systems, software, lenses, illumination systems, cameras and others. Imaging systems are further segmented into optical imaging systems and spectral imaging systems. On the basis of technique, the market is segmented into Optical Coherence Tomography (OCT), photoacoustic imaging, diffused optical tomography, hyperspectral imaging, near-infrared spectroscopy, and super-resolution microscopy.
On a therapeutic area basis, it is segmented into neurology, oncology, ophthalmology, dentistry, cardiology, dermatology, and others. On account of application, the market is segmented into pre-clinical and clinical research, pathological imaging and intraoperative imaging. According to the end-user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies. Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. Americas region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Regional Market Summary
In terms of geography, Americas dominates the market for optical imaging owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders about rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems and presence of pharmaceutical giants key players also propel the market growth in this region. For instance, according to National cancer institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the U.S. Thus, this huge patient pool is going to boost up the market growth during the forecast period.
Europe is the second largest market and holds a healthy place in global optical imaging market share due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of optical imaging over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the department of neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in optical imaging market in future.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Transthyretin Amyloidosis (ATTR) Market Competitive landscape By 2023

Transthyretin (TTR) Amyloidosis Market Information: Disease (Transthyretin (TTR) Familial Amyloid Polyneuropathy), Gender (Male & Female), Treatment (Small Molecule Treatment), & End-User (Ambulatory Surgical Center, Clinics) – Global Forecast Till 2023                                                                                                                          
Market Scenario
The Transthyretin (TTR) amyloidosis market is expected to register a sturdy growth during the forecast period.  Transthyretin (TTR) amyloidosis is a medical condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in a body's organs and tissues. It generally affects peripheral neuropathic or autonomic neuropathy system and cardiac system. The cardiac form of Transthyretin (TTR) amyloidosis puts patients at the risk of arrhythmia, cardiomegaly, and orthostatic hypertension. The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.
Top Market Players
  • Alnylam Pharmaceuticals
  • Pfizer
  • Merck
  • Ionis Pharmaceuticals Inc.
  • Corino Therapeutics Inc
  • Arcturus Therapeutics
  • Proclara Bioscience
Market Segmentation                                                                                                                          
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
The global Transthyretin (TTR) amyloidosis market is segmented on the basis of disease type, treatment, gender, and end-user. Considering the type of disease, the market is segmented into Transthyretin (TTR) familial amyloid polyneuropathy, Transthyretin (TTR) familial amyloid cardiomyopathy, and others. On the basis of treatment, the market is segmented into small molecules treatment, RNAi therapy,  organ transplantation, and others. Small molecules treatment is further segmented into tafamidis and diflunisal. On gender basis, it is segmented into male and female. According to end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others.
Regional Market Summary
Transthyretin Amyloidosis (ATTR) Market and share analysis on Regional basis, Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.
Asia Pacific is expected to be the fastest growing market. According to a report published by the United Nations in 2015the number of older people aged 60 years or over in the world is predicted to grow by 56% between 2015 and 2030, out of which 66% of the older population would reside in the Asia Pacific region. This makes the region prone to Transthyretin (TTR) amyloidosis as chances of its prevalence increases with the increasing age. Owing to a huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, and availability favorable insurance and reimbursement policies, the market growth will be accelerated during the forecast period.  Moreover, key players such as Pfizer, Merck, etc. have been setting up their regional headquarters and manufacturing plants in countries such as Singapore, China, Japan, Korea, and Australia. Thus, the growth curve of the Transthyretin (TTR) amyloidosis market will see a positive trend of growth.
Europe is the second largest market and holds a healthy global Transthyretin (TTR) amyloidosis market share. The European market is expected to exhibit robust growth during the forecast period due to major driving factors such as availability of advanced treatment facilities, increasing healthcare expenditure along with growing need for better healthcare infrastructure, and government initiatives of healthcare reform.  It is reported that in the U.K., around 60 new cases of Transthyretin (TTR) amyloidosis are reported annually, and the age-specific incidence rate of it is between 5.1 and 12.8 per million per year. Additionally, established medical device market and capability of inhabitants to afford diagnostics are aiding the market growth. However, the inefficacy of treatment and wrong diagnosis are hampering the market growth of this region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia are the largest markets owing to the development of the healthcare industry and rising availability of specialty care centers. But the market might show a steady growth due to the genetical susceptibility of Africans for transthyretin amyloidosis and government initiatives to improve the quality of healthcare in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)